Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Diagnostics Laboratory, |
RCV000021500 | SCV000891275 | likely pathogenic | X-linked Alport syndrome | 2017-12-13 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Lab, |
RCV000021500 | SCV002583544 | likely pathogenic | X-linked Alport syndrome | criteria provided, single submitter | clinical testing | ||
Fulgent Genetics, |
RCV000021500 | SCV002810354 | likely pathogenic | X-linked Alport syndrome | 2022-04-29 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003892109 | SCV004713850 | likely pathogenic | COL4A5-related condition | 2023-12-13 | criteria provided, single submitter | clinical testing | The COL4A5 c.3347G>T variant is predicted to result in the amino acid substitution p.Gly1116Val. This variant was reported in at least one individual presenting with microhematuria (Family 53, Table S1, Bekheirnia et al 2010. PubMed ID: 20378821). This variant has not been reported in a large population database, indicating this variant is rare. The p.Gly1116 residue resides in the triple-helical region (residues 42 – 1456) of the COL4A5 protein (uniprot.org). The majority of pathogenic variants in COL4A5 substitute a glycine residue to a bulkier amino acid in the triple-helical domain (Hudson et al. 1993. PubMed ID: 8253711; https://www.ncbi.nlm.nih.gov/books/NBK1207/). This variant is interpreted as likely pathogenic. |